Press Releases

Pharma Quality Control

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing

bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries, where this innovative molecular testing system is designed to transform quality control. Building on the proven success of the BIOFIRE® FILMARRAY® platform, already adopted by leading global pharmaceutical companies, BIOFIRE® SPOTFIRE® introduces a simple, small and smart approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients.

Antimicrobial Resistance

Global Agreement Announced at G7 One Health Summit to Accelerate Access to Diagnostics and Responses to Rising Health Threats

A coalition of more than 20 international partners announced the Global One Health Diagnostics Access Compact (GO-Dx) during the G7 One Health Summit in Lyon, France. This new initiative serves as a catalyst for international leaders across different sectors to advance progress toward expanding diagnostics access, enabling early detection and better surveillance, and improving response against existing and emerging threats across human, animal, and environmental health. By aligning efforts, this group aims to strengthen global preparedness through science based One Health solutions.

Business & Solutions

bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE^® SPOTFIRE^® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe

bioMérieux, a world leader in the field of in vitro diagnostics, announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/STplus) Panel and BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/STplus) Panel Mini have been CE-marked under the IVDR*. The certification includes conformity assessment for near-patient testing, enabling its use outside traditional laboratories, directly at the point of care.

Financial Information

bioMérieux – 2025 Financial Results

Consolidated sales amounted to €4,070 million in 2025, up 6.2% like-for-like from €3,980 million in the prior year period. Reported growth stood at +2.3% for the period.

Food Safety

bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality

bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of SMARTBIOME™, an innovative solution designed to help food manufacturers better understand, control and prevent microbiological spoilage. By combining high‑precision DNA sequencing, advanced bioinformatics and bioMérieux’s microbiology expertise, SMARTBIOME™ provides actionable insights to protect product quality, reduce waste and better preserve consumer safety.

Mergers & Acquisitions

bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies

bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.

WellStreet Urgent Care, bioMérieux celebrate 200,000 patients served through BIOFIRE® SPOTFIRE® tests in urgent care clinics across Georgia, Ohio and South Carolina

WellStreet Urgent Care and bioMérieux announce the 200,000th patient diagnosed via the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini in their urgent clinics since the first instrument placement in February 2025.

Business & Solutions

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of its immunoassay endocrinology offer for equine health, consisting of VIDAS® Equine INSULIN and VIDAS® Equine ACTH.

Business & Solutions

bioMérieux Honored with Multiple 2025 IMV ServiceTrak™ Clinical Laboratory Awards for Diagnostic Excellence

bioMérieux received nine 2025 IMV ServiceTrak™ Clinical Laboratory Awards for excellence in Immunoassay Analyzers, ID/AST Systems, Molecular Diagnostics and Blood Culture Systems.

Business & Solutions

Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis

Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.

Financial Information

Third-Quarter 2025 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025. Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported.

bioMérieux and Henry Ford Health host U.S. thought leaders on antimicrobial resistance to accelerate diagnostics-driven stewardship and policy

bioMérieux and Henry Ford Health partnered to host a Summit focused on promoting practical actions to address the threat posed by antimicrobial resistance.

Altesa BioSciences and bioMérieux Announce Collaboration for Altesa’s Upcoming Phase 2B COPD Clinical Trial

Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.

Financial Information

First-Half 2025 Financial Results

Consolidated sales amounted to €2,044 million in the first-half of 2025 from €1,902 million in the prior year period, a +9.4% like-for-like growth.

OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence 

OhioHealth joins bioMérieux’s AMS Centers of Excellence, advancing diagnostics to fight antimicrobial resistance and improve patient outcomes.